Topical compositions comprising benfotiamine and pyridoxamine

Details Topical compositions comprising benfotiamine and pyridoxamine Topical compositions comprising benfotiamine and pyridoxamine

2005-08-31

2010-02-23

Yu, Gina C (Department: 1611)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Cosmetic, antiperspirant, dentifrice

C546S300000, C544S171000

Reexamination Certificate

active

07666442

ABSTRACT:
The present invention provides a composition comprising an effective amount of benfotiamine and an effective amount of pyridoxamine in a suitable vehicle for topical application. The present compositions are useful in improving the appearance of aged skin characterized by wrinkles, loss of elasticity, and hyperpigmentation caused by chronoaging and/or photoaging of skin, by inhibiting particularly skin damage resulting from reactive carbonyl species (RCS), glycation of skin proteins, formation of advanced glycation endproducts (AGEs) and formation of advanced lipoxidation endproducts (ALEs).

REFERENCES:
patent: 3819480 (1974-06-01), Hochshild
patent: 5443834 (1995-08-01), Aki et al.
patent: 5723502 (1998-03-01), Proctor
patent: 5869672 (1999-02-01), Kozikowski et al.
patent: 6011067 (2000-01-01), Hersh
patent: 6083529 (2000-07-01), Manzo et al.
patent: 6093404 (2000-07-01), Kattan
patent: 6165500 (2000-12-01), Cevc
patent: 6261598 (2001-07-01), Runge et al.
patent: 6310092 (2001-10-01), Kelleher et al.
patent: 6447820 (2002-09-01), Niazi
patent: 6455589 (2002-09-01), Ames et al.
patent: 6465421 (2002-10-01), Duranton et al.
patent: 6740668 (2004-05-01), Baynes et al.
patent: 6750209 (2004-06-01), Hudson et al.
patent: 6759065 (2004-07-01), Ruijten
patent: 6783754 (2004-08-01), Mankovitz
patent: 2003/0165456 (2003-09-01), Duffy et al.
patent: 2003/0190337 (2003-10-01), Bissett
patent: 2004/0092482 (2004-05-01), Gupta
patent: 2004/0122061 (2004-06-01), Khalifah
patent: 2005/0019354 (2005-01-01), Perricone
patent: WO 02/13838 (2002-02-01), None
U.S. Department of Health and Human Services—Food and Drug Administation—Center of Drug Evaluation and Research(CDER)—Center for Biologics Evaluation and Research(CBER), Guidance for Industry(Container Closure Systems for Packaging Human Drugs and Biologics), Chemistry, Manufacuring and Controls Documentation, May 1999.
Fusaro, Ramon M. et al. 2005. The Maillard Reaction for Sunlight Protection.Ann. N. Y. Acad. Sci. 1043:174-183.
Haupt, E. et al. 2005 Benfotiamine in the treatment of diabetic polyneuropathy—a three-week randomized, controlled pilot study (BEDIP Study).International Journal of Clinical Pharmacology and Therapeutics43(2)71-77.
Hartog, Jasper W.L. et al. 2005. Accumulation of Advanced Glycation End Products, Measured as Skin Autofluorescence, in Renal Disease.Ann. N. Y. Acad. Sci.1043:299-307.
Pageon, Hervé and Daniel Asselineau. 2005. An in Vitro Approach to the Chronological Aging of Skin by Glycation of the Collagen. The Biological Effect of Glycation on the Reconstructed Skin Model.Ann. N. Y. Acad. Sci.1043:529-532.
Voziyan, Paul A. and Billy G. Hudson. 2005. Pyridoxamine. The Many Virtues of a Maillard Reaction Inhibitor.Ann. N. Y. Acad. Sci.1043:807-816.
Chumnantana, R. et al. 2004. Vitamin B6compounds prevent the death of yeast cells due to menadione, a reactive oxygen generator.Biochimica et Biophysica Acta1722:84-91.
Menè, Paolo et al. 2003. Clinical Potential of Advanced Glycation End-Product Inhibitors in Diabetes Mellitus.Am. J. Cardiovasc. Drugs3(5):315-320.
Vasan, Sara et al. 2003. Therapeutic potential of breakers of advanced glycation end product-protein crosslinks.Archives of Biochemistry and Biophysics419:89-96.
Squier, Thomas C. 2001. Oxidative stress and protein aggregation during biological aging.Experimental Gerontology36:1539-1550.
Verzijl, Nicole et al. Effect of Collagen Turnover on the Accumulation of Advanced Glycation End Products.The Journal of Biological Chemistry275(50):39027-39031.
Price, David L. et al. 2001. Chelating Activity of Advanced Glycation End-product Inhibitors.The Journal of Biological Chemistry276(52):48967-48972.
Khalifah, Raja G. et al. 1999. Amadorins: Novel Post-Amadori Inhibitors of Advanced Glycation Reactions.Biochemical and Biophysical Research Communications257:251-258.
Woelk, H. et al. 1998. Benfotiamine in Treatment of Alcoholic Polyneuropathy: An 8-Week Randomized Controlled Study (BAP I Study).Alcohol&Alcoholism33(6):631-638.
Stracke, H. et al. 1996. A Benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy.Exp. Clin. Endocrinol. Diabetes104:311-316.
PCT International Search Report for International Application No. PCT/US05/31144, dated Oct. 11, 2006.

Affiliated with

Also associated with

Rating

Topical compositions comprising benfotiamine and pyridoxamine does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Topical compositions comprising benfotiamine and pyridoxamine, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical compositions comprising benfotiamine and pyridoxamine will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4223959